Cerus (NASDAQ:CERS) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Monday, February 4th.
A number of other equities analysts have also recently commented on CERS. Zacks Investment Research cut shares of Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. BidaskClub raised shares of Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, December 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price objective on shares of Cerus in a research report on Monday, December 10th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Cerus currently has an average rating of “Buy” and a consensus target price of $8.50.
Shares of Cerus stock traded up $0.34 during trading on Monday, reaching $6.85. The company’s stock had a trading volume of 1,242,319 shares, compared to its average volume of 549,968. The stock has a market capitalization of $929.48 million, a price-to-earnings ratio of -15.57 and a beta of 1.41. Cerus has a fifty-two week low of $4.18 and a fifty-two week high of $8.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.48 and a quick ratio of 3.17.
Cerus (NASDAQ:CERS) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The business had revenue of $16.50 million during the quarter, compared to analyst estimates of $18.74 million. Cerus had a negative net margin of 74.95% and a negative return on equity of 68.90%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) earnings per share. Analysts anticipate that Cerus will post -0.38 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Cerus by 1.2% in the 4th quarter. BlackRock Inc. now owns 10,794,407 shares of the biotechnology company’s stock valued at $54,727,000 after buying an additional 123,643 shares during the last quarter. Vanguard Group Inc grew its position in Cerus by 2.4% in the 3rd quarter. Vanguard Group Inc now owns 6,626,832 shares of the biotechnology company’s stock valued at $47,779,000 after buying an additional 154,112 shares during the last quarter. Vanguard Group Inc. grew its position in Cerus by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,626,832 shares of the biotechnology company’s stock valued at $47,779,000 after buying an additional 154,112 shares during the last quarter. ARK Investment Management LLC grew its position in Cerus by 14.1% in the 3rd quarter. ARK Investment Management LLC now owns 6,499,032 shares of the biotechnology company’s stock valued at $46,858,000 after buying an additional 803,661 shares during the last quarter. Finally, Elk Creek Partners LLC boosted its position in shares of Cerus by 11.4% during the 4th quarter. Elk Creek Partners LLC now owns 5,755,232 shares of the biotechnology company’s stock worth $29,179,000 after purchasing an additional 586,820 shares in the last quarter. Hedge funds and other institutional investors own 61.40% of the company’s stock.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Featured Article: What are the Benefits of Index Funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.